au Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at fordelene ved Ultratard er større end risiciene ved behandling af diabetes.
ge The Committee for Medicinal products for Human Use (CHMP) decided that Ultratard’ s benefits are greater than its risks for the treatment of diabetes.